Key facts
- Exsure’s last known valuation is $1.6M (Jan 2025).
- It has raised $350K; the latest was Seed Round ($350K) in Jan 2025.
- Notable investors include Unicorn India Ventures, Venture Center, IIT Mandi Catalyst, Okinawa Institute of Science and Technology.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Exsure
- ·The full record, as it builds
Funding rounds
No funding rounds for Exsure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Exsure
Operator of a biotech platform intended to reduce the toxic effects of chemotherapy and improve cancer treatment outcomes. The company offers a patented exosome-based drug delivery system transforming cancer treatment with exosome-based drug delivery that targets both tumors and cancer stem cells, reducing chemotherapy side effects and relapse, enabling cancer patients, particularly with cancer stem cells, to experience targeted therapy with reduced side effects.
- Sector
- Healthcare
- HQ
- Bhubaneswar, India
- Founded
- 2021
- Employees
- 7
- Website
- exsure.in/
- Ownership
- Privately Held (backing)
Exsure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Exsure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Exsure in its N-PORT filings yet. We sweep new filings monthly.